Also planned is a new R&D pilot plant that will produce medicines for clinical trials, said GSK, adding that the programme will "establish Marietta as an innovation and manufacturing hub capable ...

The deal follows GSK’s decision to pump $800m into a new vaccines drug substance facility and R&D pilot plant in the US, with the planned investment set to double the size of the company’s ...

At the start of the pandemic GlaxoSmithKline made its vaccine booster tech available looking for collaborations with other vaccine developers – but GSK has ... a trial of the plant-based vaccine ...